Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Sep;62(3):378–384. doi: 10.1038/bjc.1990.302

P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.

G J Badiner 1, B C Moy 1, K S Smith 1, W G Tarpley 1, V E Groppi 1, B K Bhuyan 1
PMCID: PMC1971454  PMID: 2145026

Abstract

Menogaril is an anthracycline presently in Phase II clinical trials. Menogaril-resistant mouse leukaemia P388 cells were developed in vitro by 4 months of exposure to step-wise increasing concentrations of menogaril after which resistant cells (P388/MEN) were cloned in 320 ng ml-1 menogaril. P388/MEN cells were 40-fold more resistant to menogaril in vitro compared to P388/O and were also resistant in vivo. Resistance to menogaril was stable for at least 2 months in the absence of the drug. The results indicate that P388/MEN, although resistant to an anthracycline, did not display the typical multidrug resistant phenotype. It was not cross-resistant to several structurally unrelated drugs such as actinomycin D, cisplatin, or vinblastine, but it was cross-resistant to the anthracycline, adriamycin. Uptake and efflux of menogaril was similar in sensitive and resistant cell lines. Also, resistance was not reversed by verapamil. No major karyotypic difference was noted between P388/O and P388/MEN. There was no significant amplification or overexpression of the mdr gene in P388/MEN compared to P388/O. In contrast to P388/MEN, P388 cells resistant to adriamycin displayed the typical multidrug resistant phenotype. Glutathione content of P388/MEN cells was similar to that of P388/O and depletion of glutathione did not potentiate menogaril cytotoxicity. Therefore, we conclude that glutathione is not likely to be involved in menogaril resistance to P388/MEN cells.

Full text

PDF
378

Images in this article

382Figure 4
on p.382

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badiner G. J., Hamilton R. D., Li L. H., Bhuyan B. K. Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells. Invest New Drugs. 1987;5(3):219–229. doi: 10.1007/BF00175291. [DOI] [PubMed] [Google Scholar]
  2. Bech-Hansen N. T., Till J. E., Ling V. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol. 1976 May;88(1):23–31. doi: 10.1002/jcp.1040880104. [DOI] [PubMed] [Google Scholar]
  3. Beran M., Andersson B. S. Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. Cancer Res. 1987 Apr 1;47(7):1897–1904. [PubMed] [Google Scholar]
  4. Bhuyan B. K., Blowers C. L., Shugars K. D. Lethality of nogalamycin, nogalamycin analogs, and adriamycin to cells in different cell cycle phases. Cancer Res. 1980 Oct;40(10):3437–3442. [PubMed] [Google Scholar]
  5. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  6. Danks M. K., Yalowich J. C., Beck W. T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 1987 Mar 1;47(5):1297–1301. [PubMed] [Google Scholar]
  7. Deffie A. M., Alam T., Seneviratne C., Beenken S. W., Batra J. K., Shea T. C., Henner W. D., Goldenberg G. J. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res. 1988 Jul 1;48(13):3595–3602. [PubMed] [Google Scholar]
  8. Deffie A. M., Batra J. K., Goldenberg G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 1989 Jan 1;49(1):58–62. [PubMed] [Google Scholar]
  9. Dusre L., Mimnaugh E. G., Myers C. E., Sinha B. K. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res. 1989 Feb 1;49(3):511–515. [PubMed] [Google Scholar]
  10. Feinberg A. P., Vogelstein B. "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem. 1984 Feb;137(1):266–267. doi: 10.1016/0003-2697(84)90381-6. [DOI] [PubMed] [Google Scholar]
  11. Green J. A., Vistica D. T., Young R. C., Hamilton T. C., Rogan A. M., Ozols R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 1984 Nov;44(11):5427–5431. [PubMed] [Google Scholar]
  12. Gros P., Croop J., Roninson I., Varshavsky A., Housman D. E. Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc Natl Acad Sci U S A. 1986 Jan;83(2):337–341. doi: 10.1073/pnas.83.2.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hamilton T. C., Winker M. A., Louie K. G., Batist G., Behrens B. C., Tsuruo T., Grotzinger K. R., McKoy W. M., Young R. C., Ozols R. F. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 1985 Jul 15;34(14):2583–2586. doi: 10.1016/0006-2952(85)90551-9. [DOI] [PubMed] [Google Scholar]
  14. Harker W. G., Sikic B. I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 1985 Sep;45(9):4091–4096. [PubMed] [Google Scholar]
  15. Johnson R. K., Chitnis M. P., Embrey W. M., Gregory E. B. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep. 1978 Oct;62(10):1535–1547. [PubMed] [Google Scholar]
  16. Kartner N., Shales M., Riordan J. R., Ling V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res. 1983 Sep;43(9):4413–4419. [PubMed] [Google Scholar]
  17. Kaye S., Merry S. Tumour cell resistance to anthracyclines--a review. Cancer Chemother Pharmacol. 1985;14(2):96–103. doi: 10.1007/BF00434344. [DOI] [PubMed] [Google Scholar]
  18. Klohs W. D., Steinkampf R. W., Havlick M. J., Jackson R. C. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Cancer Res. 1986 Sep;46(9):4352–4356. [PubMed] [Google Scholar]
  19. Li L. H., Kuentzel S. L., Murch L. L., Pschigoda L. M., Krueger W. C. Comparative biological and biochemical effects of nogalamycin and its analogs on L1210 leukemia. Cancer Res. 1979 Dec;39(12):4816–4822. [PubMed] [Google Scholar]
  20. Ling V., Thompson L. H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974 Feb;83(1):103–116. doi: 10.1002/jcp.1040830114. [DOI] [PubMed] [Google Scholar]
  21. McGovren J. P. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia. Cancer Treat Rep. 1980 Apr-May;64(4-5):727–729. [PubMed] [Google Scholar]
  22. McGovren J. P., Hamilton R. D., Adams W. J., Pratt E. A. Quantitation of anthracycline antitumor agent menogarol in plasma using liquid chromatography with fluorescence detection. Anal Chem. 1984 Aug;56(9):1587–1590. doi: 10.1021/ac00273a011. [DOI] [PubMed] [Google Scholar]
  23. McGovren J. P., Neil G. L., Denlinger R. H., Hall T. L., Crampton S. L., Swenberg J. A. Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent. Cancer Res. 1979 Dec;39(12):4849–4855. [PubMed] [Google Scholar]
  24. Nakashima K., Nishida K., Nakatsuji S., Akiyama S. Development and application of organic reagents for analysis. VIII. Determination of biological thiols with a new fluorogenic thiol-selective reagent, N-(p-[2-(6-dimethylamino)benzofuranyl]phenyl)maleimide. Chem Pharm Bull (Tokyo) 1986 Apr;34(4):1678–1683. doi: 10.1248/cpb.34.1678. [DOI] [PubMed] [Google Scholar]
  25. Neil G. L., Kuentzel S. L., McGovren J. P. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1971–1978. [PubMed] [Google Scholar]
  26. Peterson W. D., Jr, Simpson W. F., Hukku B. Cell culture characterization: monitoring for cell identification. Methods Enzymol. 1979;58:164–178. doi: 10.1016/s0076-6879(79)58134-8. [DOI] [PubMed] [Google Scholar]
  27. Ramu A., Cohen L., Glaubiger D. Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells. Cancer Res. 1984 May;44(5):1976–1980. [PubMed] [Google Scholar]
  28. Riordan J. R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. 1985 Aug 29-Sep 4Nature. 316(6031):817–819. doi: 10.1038/316817a0. [DOI] [PubMed] [Google Scholar]
  29. Robertson S. M., Ling V., Stanners C. P. Co-amplification of double minute chromosomes, multiple drug resistance, and cell surface P-glycoprotein in DNA-mediated transformants of mouse cells. Mol Cell Biol. 1984 Mar;4(3):500–506. doi: 10.1128/mcb.4.3.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schabel F. M., Jr, Skipper H. E., Trader M. W., Laster W. R., Jr, Griswold D. P., Jr, Corbett T. H. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep. 1983 Oct;67(10):905–922. [PubMed] [Google Scholar]
  31. Slovak M. L., Hoeltge G. A., Dalton W. S., Trent J. M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 1988 May 15;48(10):2793–2797. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES